Market Research Logo

Liver Transplant Rejection - Pipeline Review, H2 2016

Liver Transplant Rejection - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Liver Transplant Rejection - Pipeline Review, H2 2016’, provides an overview of the Liver Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Liver Transplant Rejection
    • The report reviews pipeline therapeutics for Liver Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Liver Transplant Rejection therapeutics and enlists all their major and minor projects
    • The report assesses Liver Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Liver Transplant Rejection
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Liver Transplant Rejection
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Liver Transplant Rejection pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Liver Transplant Rejection Overview
    Therapeutics Development
    Pipeline Products for Liver Transplant Rejection - Overview
    Pipeline Products for Liver Transplant Rejection - Comparative Analysis
    Liver Transplant Rejection - Therapeutics under Development by Companies
    Liver Transplant Rejection - Therapeutics under Investigation by Universities/Institutes
    Liver Transplant Rejection - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Liver Transplant Rejection - Products under Development by Companies
    Liver Transplant Rejection - Products under Investigation by Universities/Institutes
    Liver Transplant Rejection - Companies Involved in Therapeutics Development
    Astellas Pharma Inc.
    Biogen Inc
    Conatus Pharmaceuticals Inc.
    Digna Biotech, S.L.
    Dompe Farmaceutici S.p.A.
    Novartis AG
    RedHill Biopharma Ltd.
    Liver Transplant Rejection - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    ABC-294640 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cardiotrophin-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Liver Transplantation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Liver Transplantation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    emricasan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    everolimus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FX-06 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    reparixin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tacrolimus ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TR-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Liver Transplant Rejection - Dormant Projects
    Liver Transplant Rejection - Discontinued Products
    Liver Transplant Rejection - Product Development Milestones
    Featured News & Press Releases
    Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
    May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients
    Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting
    Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules
    Oct 20, 2011: European Medicines Agency Agrees To Precautionary Recall Of Advagraf 0.5mg Capsule Batches
    Jul 01, 2011: Astellas Introduces Advagraf In India
    Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I
    Feb 18, 2011: Astellas Introduces Advagraf in China-once daily administration, leading the new trend in immunosuppressive therapy after organ transplant
    Oct 02, 2007: New Once-Daily Advagraf Launched Across Europe.
    Jun 18, 2007: Advagraf Now Available in Germany and the UK as a Once-Daily Immunosuppressant in Organ Transplantation
    Apr 30, 2007: Advagraf Now Approved Across Europe as a Once-Daily Immunosuppressant in Organ Transplantation.
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Liver Transplant Rejection, H2 2016
    Number of Products under Development for Liver Transplant Rejection - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Liver Transplant Rejection - Pipeline by Astellas Pharma Inc., H2 2016
    Liver Transplant Rejection - Pipeline by Biogen Inc, H2 2016
    Liver Transplant Rejection - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
    Liver Transplant Rejection - Pipeline by Digna Biotech, S.L., H2 2016
    Liver Transplant Rejection - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
    Liver Transplant Rejection - Pipeline by Novartis AG, H2 2016
    Liver Transplant Rejection - Pipeline by RedHill Biopharma Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Liver Transplant Rejection - Dormant Projects, H2 2016
    Liver Transplant Rejection - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Liver Transplant Rejection, H2 2016
    Number of Products under Development for Liver Transplant Rejection - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report